NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis

Overview

Información sobre este estudio

The purpose of this study is to examine the effectivenessof intraarticular ketorolac versus intraarticular triamcinolone in treating symptoms of moderate to advanced primary osteoarthritis of the basilar thumb. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Adults ≥ 40 years of age.
  • Pain at the thumb base brought on by direct pressure (grind test) and with movement.
  • Pain resistant to previous conservative management with oral analgesics, NSAIDs, icing, and splinting.
  • Radiological observation indicative of arthritis based on the Eaton-Littler classification system (stages 1 through 4).
  • Patient understands the protocol and signed the informed consent.
  • Patient is covered by health insurance.

Exclusion Criteria: 

  • Known allergy to either of the treatment products.
  • Patient’s analgesic treatment regimen was modified within four weeks before trial inclusion.
  • Scaphoid-trapezial arthritis present.
  • Localized or systemic infection.
  • Previous thumb surgery on study thumb.
  • Previous thumb injury on study thumb.
  • Patient with inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis).
  • Severe and/or uncontrolled hypertension.
  • De Quervain tendinopathy present.
  • History of injection to the trapeziometacarpal joint on study thumb within the previous 6 weeks.
  • Uncontrolled diabetes.
  • Pregnant or lactating females. Female participants of childbearing potential must have a negative pregnancy test before the injection. Women without childbearing potential (ie., surgically sterile with hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible to participate without completing a pregnancy.
  • Immunodeficient patients.
  • Patients that are currently using nicotine products, or who have quit in the last 12 months.
  • Patients under guardianship, curatorship, or are otherwise not self-sufficient.
  • Patients participating in another clinical research trial which interferes with this study protocol or outcomes.
  • Patients unable to follow the protocol in the investigators’ judgement.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/19/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Marco Rizzo, M.D.

Abierto para la inscripción

Contact information:

Marco Rizzo M.D.

(507) 284-6434

Rizzo.Marco@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20548341

Mayo Clinic Footer